Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway

DMM Disease Models and Mechanisms

Volumn 8, Issue 9, 2015, Pages 1047-1057

  Szlachcic, Wojciech J ^a   Switonski, Pawel M ^a   Krzyzosiak, Wlodzimierz J ^a   Figlerowicz, Marek ^a   Figiel, Maciej ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

Huntington disease; IPS; IPSC; MAPK pathway; P53 pathway; SOD1; Wnt pathway

Indexed keywords

BETA CATENIN; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; HUNTINGTIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXIREDOXIN 1; PROTEIN P53; HTT PROTEIN, HUMAN; HTT PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; SOD1 PROTEIN, HUMAN; SOD1 PROTEIN, MOUSE; SUPEROXIDE DISMUTASE; TP53 PROTEIN, HUMAN; WNT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN FIBROBLAST; TERATOMA; WNT SIGNALING PATHWAY; ANIMAL; CHILD; CYTOLOGY; DISEASE MODEL; ENZYME ACTIVATION; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; YOUNG ADULT;

ANIMALS; BASE SEQUENCE; BETA CATENIN; CELL DIFFERENTIATION; CHILD; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; ENZYME ACTIVATION; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELLS; MAP KINASE SIGNALING SYSTEM; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OXIDATIVE STRESS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE-1; TUMOR SUPPRESSOR PROTEIN P53; WNT PROTEINS; YOUNG ADULT;

EID: 84941550030     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.019406     Document Type: Article

References (62)

1. An, M. C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney, S., Melov, S. and Ellerby, L. M. (2012). Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253-263.
2. Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A. et al. (2005). p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41.
3. Bikkavilli, R. K. and Malbon, C. C. (2009). Mitogen-activated protein kinases and Wnt/beta-catenin signaling: molecular conversations among signaling pathways. Commun. Integr. Biol. 2, 46-49.
4. Bodai, L. and Marsh, J. L. (2012). A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology. BioEssays 34, 142-148.
5. Bowles, K. R. and Jones, L. (2014). Kinase signalling in Huntington's Disease. J. Huntingt. Dis. 3, 89-123.
6. Brooks, S. P., Jones, L. and Dunnett, S. B. (2012). Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease. Brain Res. Bull. 88, 81-93.
7. Carmichael, J., Sugars, K. L., Bao, Y. P. and Rubinsztein, D. C. (2002). Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277, 33791-33798.
8. Castiglioni, V., Onorati, M., Rochon, C. and Cattaneo, E. (2012). Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Neurobiol. Dis. 46, 30-40.
9. Caviston, J. P. and Holzbaur, E. L. F. (2009). Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 19, 147-155.
10. Chae, J.-I., Kim, D.-W., Lee, N., Jeon, Y.-J., Jeon, I., Kwon, J., Kim, J., Soh, Y., Lee, D.-S., Seo, K. S. et al. (2012). Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem. J. 446, 359-371.
11. Chan, A. W. S., Cheng, P.-H., Neumann, A. and Yang, J.-J. (2010). Reprogramming Huntington monkey skin cells into pluripotent stem cells. Cell Reprogram. 12, 509-517.
12. Conforti, P., Camnasio, S., Mutti, C., Valenza, M., Thompson, M., Fossale, E., Zeitlin, S., MacDonald, M. E., Zuccato, C. and Cattaneo, E. (2013). Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. Neurobiol. Dis. 50, 160-170.
13. Cummings, D. M., Milnerwood, A. J., Dallerac, G. M., Waights, V., Brown, J. Y., Vatsavayai, S. C., Hirst, M. C. and Murphy, K. P. S. J. (2006). Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 15, 2856-2868.
14. Dupont, P., Besson, M.-T., Devaux, J. and Lievens, J.-C. (2012). Reducing canonical Wingless/Wnt signaling pathway confers protection against mutant Huntingtin toxicity in Drosophila. Neurobiol. Dis. 47, 237-247.
15. Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J. P., Gusella, J. F., Joyner, A. L. et al. (1995). Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410.
16. Ehrnhoefer, D. E., Skotte, N. H., Ladha, S., Nguyen, Y. T. N., Qiu, X., Deng, Y., Huynh, K. T., Engemann, S., Nielsen, S. M., Becanovic, K. et al. (2014). p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum. Mol. Genet. 23, 717-729.
17. Essers, M. A. G., de Vries-Smits, L. M. M., Barker, N., Polderman, P. E., Burgering, B. M. T. and Korswagen, H. C. (2005). Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308, 1181-1184.
18. Fiszer, A., Olejniczak, M., Galka-Marciniak, P., Mykowska, A. and Krzyzosiak, W. J. (2013). Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res. 41, 10426-10437.
19. Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C. et al. (2013). STRING v9. 1: proteinprotein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815.
20. Galli, S., Lopes, D. M., Ammari, R., Kopra, J., Millar, S. E., Gibb, A. and Salinas, P. C. (2014). Deficient Wnt signalling triggers striatal synaptic degeneration and impaired motor behaviour in adult mice. Nat. Commun. 5, 4992.
21. Gladding, C. M., Fan, J., Zhang, L. Y. J., Wang, L., Xu, J., Li, E. H. Y., Lombroso, P. J. and Raymond, L. A. (2014). Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. J. Neurochem. 130, 145-159.
22. Godin, J. D., Poizat, G., Hickey, M. A., Maschat, F. and Humbert, S. (2010). Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J. 29, 2433-2445.
23. Hands, S., Sajjad, M. U., Newton, M. J. and Wyttenbach, A. (2011). In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J. Biol. Chem. 286, 44512-44520.
24. Hodges, A., Strand, A. D., Aragaki, A. K., Kuhn, A., Sengstag, T., Hughes, G., Elliston, L. A., Hartog, C., Goldstein, D. R., Thu, D. et al. (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15, 965-977.
25. Hu, Y., Chopra, V., Chopra, R., Locascio, J. J., Liao, Z., Ding, H., Zheng, B., Matson, W. R., Ferrante, R. J., Rosas, H. D. et al. (2011). Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc. Natl. Acad. Sci. USA 108, 17141-17146.
26. Jacobsen, J. C., Gregory, G. C., Woda, J. M., Thompson, M. N., Coser, K. R., Murthy, V., Kohane, I. S., Gusella, J. F., Seong, I. S., MacDonald, M. E. et al. (2011). HD CAG-correlated gene expression changes support a simple dominant gain of function. Hum. Mol. Genet. 20, 2846-2860.
27. Jeon, I., Lee, N., Li, J.-Y., Park, I.-H., Park, K. S., Moon, J., Shim, S. H., Choi, C., Chang, D.-J., Kwon, J. et al. (2012). Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 30, 2054-2062.
28. Ji, H., Wang, J., Nika, H., Hawke, D., Keezer, S., Ge, Q., Fang, B., Fang, X., Fang, D., Litchfield, D. W. et al. (2009). EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol. Cell 36, 547-559.
29. Ko, J., Ou, S. and Patterson, P. H. (2001). New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319-329.
30. Kuhn, A., Goldstein, D. R., Hodges, A., Strand, A. D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M. A., Sathasivam, K., Cha, J.-H. J. et al. (2007). Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16, 1845-1861.
31. Lengner, C. J., Camargo, F. D., Hochedlinger, K., Welstead, G. G., Zaidi, S., Gokhale, S., Scholer, H. R., Tomilin, A. and Jaenisch, R. (2007). Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 1, 403-415.
32. Lim, N. K. H., Hung, L. W., Pang, T. Y., Mclean, C. A., Liddell, J. R., Hilton, J. B., Li, Q.-X., White, A. R., Hannan, A. J. and Crouch, P. J. (2014). Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Hum. Mol. Genet. 23, 4051-4063.
33. Liot, G., Zala, D., Pla, P., Mottet, G., Piel, M. and Saudou, F. (2013). Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci. 33, 6298-6309.
34. Maher, P., Dargusch, R., Bodai, L., Gerard, P. E., Purcell, J. M. and Marsh, J. L. (2011). ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet. 20, 261-270.
35. Mattis, V. B., Tom, C., Akimov, S., Saeedian, J., Østergaard, M. E., Southwell, A. L., Doty, C. N., Ornelas, L., Sahabian, A., Lenaeus, L. et al. (2015). HD iPSCderived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum. Mol. Genet. 24, 3257-3271.
36. Milnerwood, A. J., Cummings, D. M., Dallerac, G. M., Brown, J. Y., Vatsavayai, S. C., Hirst, M. C., Rezaie, P. and Murphy, K. P. S. J. (2006). Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 15, 1690-1703.
37. Molero, A. E., Gokhan, S., Gonzalez, S., Feig, J. L., Alexandre, L. C. and Mehler, M. F. (2009). Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc. Natl. Acad. Sci. USA 106, 21900-21905.
38. Molina-Calavita, M., Barnat, M., Elias, S., Aparicio, E., Piel, M. and Humbert, S. (2014). Mutant huntingtin affects cortical progenitor cell division and development of the mouse neocortex. J. Neurosci. 34, 10034-10040.
39. Munji, R. N., Choe, Y., Li, G., Siegenthaler, J. A. and Pleasure, S. J. (2011). Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors. J. Neurosci. 31, 1676-1687.
40. Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G. and Hayden, M. R. (1995). Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811-823.
41. Nguyen, G. D., Molero, A. E., Gokhan, S. and Mehler, M. F. (2013). Functions of huntingtin in germ layer specification and organogenesis. PLoS ONE 8, e72698.
42. Papoutsi, M., Labuschagne, I., Tabrizi, S. J. and Stout, J. C. (2014). The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation. Mov. Disord. 29, 673-683.
43. Parker, J. A., Vazquez-Manrique, R. P., Tourette, C., Farina, F., Offner, N., Mukhopadhyay, A., Orfila, A.-M., Darbois, A., Menet, S., Tissenbaum, H. A. et al. (2012). Integration of-catenin, sirtuin, and FOXO signaling protects from mutant huntingtin toxicity. J. Neurosci. 32, 12630-12640.
44. Paulsen, J. S., Langbehn, D. R., Stout, J. C., Aylward, E., Ross, C. A., Nance, M., Guttman, M., Johnson, S., MacDonald, M., Beglinger, L. J. et al. (2008). Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79, 874-880.
45. Penney, J. B., Vonsattel, J.-P., MacDonald, M. E., Gusella, J. F. and Myers, R. H. (1997). CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41, 689-692.
46. Ribeiro, M., Rosenstock, T. R., Cunha-Oliveira, T., Ferreira, I. L., Oliveira, C. R. and Rego, A. C. (2012). Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells. Free Radic. Biol. Med. 53, 1857-1867.
47. Roos, R. A. C. (2010). Huntington's disease: a clinical review. Orphanet J. Rare Dis. 5, 40.
48. Rossant, J. (2015). Mouse and human blastocyst-derived stem cells: vive les differences. Development 142, 9-12.
49. Saavedra, A., Giralt, A., Rue, L., Xifro, X., Xu, J., Ortega, Z., Lucas, J. J., Lombroso, P. J., Alberch, J. and Perez-Navarro, E. (2011). Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J. Neurosci. 31, 8150-8162.
50. Schippling, S., Schneider, S. A., Bhatia, K. P., Mu nchau, A., Rothwell, J. C., Tabrizi, S. J. and Orth, M. (2009). Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol. Psychiatry 65, 959-965.
51. Slow, E. J., van Raamsdonk, J., Rogers, D., Coleman, S. H., Graham, R. K., Deng, Y., Oh, R., Bissada, N., Hossain, S. M., Yang, Y.-Z. et al. (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555-1567.
52. Sorolla, M. A., Reverter-Branchat, G., Tamarit, J., Ferrer, I., Ros, J. and Cabiscol, E. (2008). Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 45, 667-678.
53. Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E. and Thompson, L. M. (2000). The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 97, 6763-6768.
54. The HD iPSC Consortium (2012). Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264-278.
55. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
56. Tourette, C., Farina, F., Vazquez-Manrique, R. P., Orfila, A.-M., Voisin, J., Hernandez, S., Offner, N., Parker, J. A., Menet, S., Kim, J. et al. (2014). The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. PLoS Biol. 12, e1001895.
57. Valencia, A., Reeves, P. B., Sapp, E., Li, X., Alexander, J., Kegel, K. B., Chase, K., Aronin, N. and DiFiglia, M. (2010). Mutant huntingtin and glycogen synthase kinase 3-? accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J. Neurosci. Res. 88, 179-190.
58. Valencia, A., Sapp, E., Kimm, J. S., McClory, H., Reeves, P. B., Alexander, J., Ansong, K. A., Masso, N., Frosch, M. P., Kegel, K. B. et al. (2013). Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum. Mol. Genet. 22, 1112-1131.
59. Woda, J. M., Calzonetti, T., Hilditch-Maguire, P., Duyao, M. P., Conlon, R. A. and MacDonald, M. E. (2005). Inactivation of the Huntington's disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo. BMC Dev. Biol. 5, 17.
60. Yusa, K., Rad, R., Takeda, J. and Bradley, A. (2009). Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat. Methods 6, 363-369.
61. Yusa, K., Zhou, L., Li, M. A., Bradley, A. and Craig, N. L. (2011). A hyperactive piggyBac transposase for mammalian applications. Proc. Natl. Acad. Sci. USA 108, 1531-1536.
62. Zeitlin, S., Liu, J.-P., Chapman, D. L., Papaioannou, V. E. and Efstratiadis, A. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11, 155-163.